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single or double unit recipient groups. There was no signiﬁcant
difference in overall survival. However, when comparing patients
that survived 9 mo after transplant there were signiﬁcant differ-
ences. No patient in the double UCB group experienced further
events, however, in the single UCB group, there were 15 events, 13
of which were due to disease recurrence (p0.01). Collectively,
these data support the concept that the infusion of two partially
HLA matched UCB units results in rapid engraftment, a higher
rate of aGVHD and a lower rate of leukemia recurrence. We
hypothesize that the co-infusion of two, partially HLA matched
UCB units leads to increased alloreactivity and this accounts for
the above ﬁndings.
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A NOVEL TRIPLE UMBILICAL CORD BLOOD TRANSPLANT (UCBT)
STRATEGY TO PROMOTE NK CELL IMMUNOTHERAPY (UNIT 1) WITH A
FULLY ABLATIVE PREPARATIVE REGIMEN FOLLOWED BY A DOUBLE
UCBT IN PATIENTS WITH REFRACTORY AML
Jeffrey S. Miller, Claudio G. Brunstein, Sarah Cooley, Michael R.
Verneris, Angela Panoskaltsis-Mortari, Linda J. Burns, David Mc-
Kenna, Kathryn Dusenbery, Cladd Stevens, Pablo Rubenstein, Marcie
Tomblyn, Mukta Arora, Margaret L. MacMillan, Todd Defor, Chap
Le, Philip B. McGlave, Bruce R. Blazar, Daniel J. Weisdorf, and John
E. Wagner University of Minnesota, Minneapolis, MN
Previously, we tested adoptive transfer of haploidentical periph-
eral blood (PB) derived NK cells without transplantation in pa-
tients with refractory AML and demonstrated a correlation be-
tween in vivo NK cell expansion and complete remission. This
therapy is limited by: 1) the inability to expand NK cells in most
patients, 2) prolonged neutropenia and 3) inconsistent efﬁcacy. We
hypothesized that UCB-derived NK cells may show better in vivo
expansion because UCB is rich in NK cell precursors. Therefore,
we tested our triple UCBT strategy in patients with refractory
relapsed AML. UCB-derived NK cells (matched at 3 HLA loci and
KIR-ligand mismatched when possible) were infused (after CD3
depletion and IL-2 activation) on day –12 after conditioning with
cyclophosphamide, ﬂudarabine and TBI. Subcutaneous IL-2 (10
MU  6) was given over 10 days to facilitate in vivo NK cell
expansion. On day 0, two UCB units ( 4/6 match) were trans-
planted (DCBT). Ten patients have been treated and unexpect-
edly, four patients exhibited neutrophil engraftment from the pro-
cessed and IL-2 activated NK cell Unit #1. One patient developed
cyclophosphamide induced cardiac failure and died prior to
DCBT. All others tolerated the NK infusion and IL-2 without
unexpected toxicity and were leukemia-free at the time of engraft-
ment. Two remain alive and disease free at 3 and 8months and
three died disease free of TRM. Four have relapsed after initially
clearing their leukemia. These data suggest UCB NK cells may be
administered safely and, despite CD3 depletion and IL-2 activation
(ex vivo and in vivo), provide long-term engraftment potential that
may dominate over unmanipulated UCB infused subsequently. In
summary, UCB is a rich source of NK precursors capable of in vivo
expansion which are potentially better suited than adult NK cells
for use in treatment of patients with refractory AML.
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EX-VIVO EXPANSION AND MRNA TRANSFECTION OF CORD BLOOD
DERIVED NATURAL KILLER CELLS
Hans Klingemann, Hande H. Tuncer, Laurent Boissel, Monica Betan-
cur, Curtis Cetrulo, Robb Friedman, Adam Wolfberg Tufts-New En-
gland Medical Center, Molecular Oncology Research Institute, Tufts
University School of Medicine, Boston, MA
Natural Killer (NK) cell-mediated alloreactivity can control leu-
kemia relapse while protecting patients from graft-versus-host dis-
ease (GVHD) after allogeneic stem cell transplant. Cord blood
(CB) is rich in NK cell progenitors and represents an attractive
platform for cytotoxic cell therapy. Our objective was to ex-vivo
expand cord blood NK cells followed by genetic modiﬁcation to
ultimately render them cancer cell speciﬁc by introducing chimeric
antigen receptors. CB mononuclear cells were cryopreserved after
CD3 depletion performed by immunomagnetic microbead selec-
tion (Miltenyi Biotec, Auburn, CA). Cells were plated for NK
expansion, with or without a feeder layer of irradiated umbilical
cord mesenchymal cells (UC-MSC) obtained from the Wharton’s
jelly either from the same (autologous) or from an unrelated (al-
logeneic) cord donor, with or without IL-2 (1000 IU/ml), IL-15
(10 ng/ml), IL-3 (10ng/ml) and Flt3 (10ng/ml). At a median of 19
days of culture (range 14-21), there was signiﬁcantly higher expan-
sion (range 3.5-72 fold) of CD56/CD3 cells with the UC-MSC
feeder layer and cytokines compared to controls (mean 21.2
 20.8
fold increase vs 1.6 
 0.9 fold increase with feeder layer only and
1.8
 0.89 fold increase with cytokines only, p0.039 and p0.041
respectively). There was no signiﬁcant difference in NK expansion
between autologous and allogeneic UC-MSC feeder layers (29.6

26.8 vs. 12.8
 8.9 fold, p0.243). NK cells expansion was directly
proportional to the number of UC-MSC plated as feeders. Ex-
panded CB-NK cells also displayed enhanced cytotoxicity com-
pared to control cultures plated with cytokines only (91.78
0.7%
vs. 82.5
1.8%, p0.003 and 89
2.3% vs. 83.7
0.18%, p0.056,
respectively). To test whether expanded CB-NK cells can be ge-
netically engineered for ultimately targeting malignant cells, we
transfected via electroporation (Bio-Rad) expanded CB-NK cells
with mRNA produced from plasmid GFP-cDNA. GFP-mRNA
expression (ﬂow cytometry) at 24 hours was signiﬁcantly higher
(mean 42.8
5.2%) compared to GFP-cDNA controls (mean
4.2
0.35%, p0.001). Mean GFP-mRNA expression was 35%,
31% and 16.5% at 48, 72 and 144 hours respectively. In summary,
CB-NK cells can be effectively expanded on a feeder layer of
UC-MSC while preserving cytotoxicity and can also be genetically
engineered by mRNA transfection.
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UPDATE ON THE C.W. BILL YOUNG CELL TRANSPLANTATION PRO-
GRAM & NATIONAL CORD BLOOD INVENTORY
Baitty, Robert L., Ashton, Robyn S., Gale, Randy C., Tims, Shelley E.,
Wabeke, Anita, Burdick, James F. Department of Health and Human
Services, Health Resources and Services Administration, Division of
Transplantation, Rockville, MD
The Stem Cell Therapeutic and Research Act of 2005 (Public
Law 109-129) was signed by President Bush on December 20,
2005. Administrative responsibility for most provisions of the Act
is assigned to the Health Resources and Services Administration
(HRSA) within the Department of Health and Human Services
(HHS). Section 2 of the Act authorizes Federal support for collec-
tion and maintenance of 150,000 new, high quality cord blood
units for a National Cord Blood Inventory (NCBI), authorizes a
related cord blood donor demonstration project, and requires that
some cord blood units not suitable for clinical transplantation be
made available for research. Contracts for NCBI collections are
awarded based on technical merit, the ability to recruit and collect
cord blood units from diverse populations, bank location (to ensure
geographic dispersion), and price. Contracted banks must also
demonstrate the ability to assist during catastrophic events that
may result in an increased use of umbilical cord blood for hema-
topoietic reconstitution. The six umbilical cord blood banks
awarded contracts in November, 2006 (ﬁrst cohort) are: Duke
University Medical Center and Health Systems; the University of
Texas M.D. Anderson Cancer Center; the New York Blood Cen-
ter; the Puget Sound Blood Center; StemCyte, Inc.; and, the
University of Colorado at Denver Health and Sciences. Of the
cord blood units collected and banked with the monies awarded in
2006, approximately 63% will be from racial and ethnic minorities.
HRSA has begun the competitive contracting process for a second
round of awards to cord blood banks (second cohort). Implemen-
tation of the related cord blood donor demonstration project has
begun with the publication of a request for information on HRSA’s
proposed approach in the spring of 2007. Section 3 of the Act
authorizes the C.W. Bill Young Cell Transplantation Program
(successor to the National Bone Marrow Donor Registry). Among
other functions, the C.W. Bill Young Cell Transplantation Pro-
gram (Program) is charged with creating a single point of access
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where patients and healthcare providers can search and access in a
single place, all blood stem cell sources. Additional functions in-
clude adult bone marrow donor recruitment and tissue typing
activities and the distribution of blood stem cell products for
transplantation. HRSA awarded four contracts in late ﬁscal year
2006 for the infrastructure components of the Program. The
contracts for an Ofﬁce of Patient Advocacy/Single Point of Access,
Bone Marrow Coordinating Center, and Cord Blood Coordinating
Center were awarded to the National Marrow Donor Program in
Minneapolis, Minnesota. A single contract for the Stem Cell Ther-
apeutic Outcomes Database was awarded to the Medical College of
Wisconsin’s Center for International Blood and Marrow Trans-
plant Research in Milwaukee, Wisconsin. Section 3 of the Act also
calls for establishment of an Advisory Council to advise the Sec-
retary of HHS regarding the Program and related matters, and
requires HHS to recognize one or more organizations to accredit
cord blood banks collecting units for the National Cord Blood
Inventory. Establishment of the Advisory Council on Blood Stem
Cell Transplantation is underway and the Advisory Council will be
charged with such activities as providing guidance to HRSA with
respect to completion of the recognition of an accrediting organi-
zation(s). This presentation describes HRSA’s approach to imple-
menting the new programs authorized by the Act and provides an
update on the ﬁrst year’s activities.
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